antibody therapies

Bio & Pharma Samsung, Celltrion lead biosimilar market in Europe, US

Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz in the antibody biosim...

IPOs Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut

SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...

Bio & Pharma Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug

Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...

Bio & Pharma Celltrion to establish CDMO subsidiary

Celltrion Inc., South Korea’s largest biosimilar maker, said on Friday it plans to establish a contract development and manufacturing organiza...

Bio & Pharma Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman

WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...

Bio & Pharma Samsung Life Science invests in US biotech firm Latus Bio

Samsung Life Science Fund, managed by Samsung Group’s venture investment arm, has invested in US biotechnology firm Latus Bio Inc. during the ...

Bio & Pharma Samsung targets gene therapy sector through US investments

Samsung Group is targeting the gene therapy business through investments in US biotechnology companies as the leading South Korean conglomerate is s...

Bio & Pharma Daewoong gets stem cell facility license in Indonesia

South Korea's Daewoong Pharmaceutical announced on Tuesday that its subsidiary Daewoong Biologics Indonesia has obtained a stem cell Lab Operational...

Bio & Pharma Celltrion, WuXi XDC to develop new antibody-drug conjugates

South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC)...

Bio & Pharma Lotte Biologics, NJ Bio to jointly develop ADC

South Korea's Lotte Biologics Co. announced on Monday that it has signed a strategic business agreement with NJ Bio, a US-based preclinical and clin...

Mergers & Acquisitions Orion to buy control of biotech startup LegoChem for $415 mn

South Korea’s snack and confectionery maker Orion Group has agreed to buy a controlling stake in LegoChem Biosciences Inc., a Korean biotech s...

Bio & Pharma MedPacto gets FDA OK for colorectal cancer drug clinical trial

South Korea's biotech company MedPacto Inc. announced on Tuesday that it has got approval from the US Food and Drug Administration (FDA) for its I...

Bio & Pharma S.Korea’s GC Cell targets global cell therapy CDMO business

GC Cell Corp., an affiliate of South Korea’s major pharmaceutical company GC Biopharma Corp., is targeting the cell therapy contract developme...

Bio & Pharma Celltrion, Cyron to develop multi-specific antibody new drug

South Korea’s biopharmaceutical company Celltrion Inc. announced on Wednesday that it signed a joint research agreement with domestic startup ...

Bio & Pharma 'World-class bispecific antibody technology of ABL Bio'

MADRID - "The clinical Phase 1 results of the immune-oncology candidate ABL111, developed in collaboration with ABL Bio, have been selected as the b...

Bio & Pharma Dong-A ST, UMass to jointly research for gene therapy

South Korea's Dong-A ST announced on Friday it has signed a joint research agreement with the University of Massachusetts (UMass) Chan Medical Schoo...

Bio & Pharma Lotte builds US antibody-drug conjugate plant with $82 mn

South Korea’s Lotte Biologics Co. is establishing an antibody-drug conjugate (ADC) factory in Syracuse, New York, with an investment of 110 bi...

Bio & Pharma NKMax to perform first tests on dementia cell therapy in US

NKMax Co., South Korea's largest developer of natural killer (NK) cell therapies, will conduct its first clinical trials in the US for its candidate...

Bio & Pharma HLB gets global rights to Chinese liver cancer drug

South Korea’s HLB Therapeutics Co. on Tuesday said its US subsidiary Elevar Therapeutics has acquired the global rights excluding South Kore...

Bio & Pharma NKMax's US subsidiary listed on Nasdaq

South Korean natural killer (NK) cell drugmaker NKMax Co. on Wednesday said its US subsidiary NKGen Biotech on Monday was listed on the Nasdaq Globa...

Mergers & Acquisitions SK becomes top shareholder of US contract drug maker CBM

SK Pharmteco Co., a South Korean contract development and manufacturing organization (CDMO), said on Wednesday it has secured management rights of t...

Bio & Pharma Hanmi Pharm to start global clinical trials for immune-oncology drug

South Korea's Hanmi Pharmaceutical Co. announced on Tuesday that it has received approval for the phase 1 clinical trial plan of the immune-oncology...

Bio & Pharma Gencurix joins US gov't Cancer Moonshot project

South Korean cancer molecular diagnostics company Gencurix Inc. announced on Monday that it joins US President Joe Biden's cancer-conquering project...

Bio & Pharma SK Biopharm eyes Asia's No.1 spot in radioactive drug market

South Korea’s SK Biopharmaceuticals Co. is aiming to triple its enterprise value to $15 billion by 2026 with the goal of rising to the top run...

Bio & Pharma GI Innovation seeks to license allergy therapy to Japan in 2023

South Korea’s GI Innovation Inc. aims to complete licensing of its allergic diseases treatment candidate to a Japanese drug company by year's ...

Artificial intelligence Neurophet strives to be first mover in fight against Alzheimer’s

Neurophet Inc., a South Korean startup developing artificial intelligence-powered medical solutions for brain diseases, is striving to make a breakt...

Bio & Pharma Welt gets second digital therapeutic device approval in S. Korea

South Korea's Ministry of Food and Drug Safety announced on Wednesday that it has approved the cognitive therapy software "WELT-I" developed by We...

Bio & Pharma Vaxcell-bio's NK cell therapy wins therapeutic approval for liver cancer

South Korean anti-cancer immunotherapy company Vaxcell-Bio Therapeutics announced on Friday that its natural killer (NK) cell therapy, Vax-NK/HCC, h...

Bio & Pharma Verismo's CAR-T therapy designated fast-track status by FDA

Verismo Therapeutics, a US affiliate of South Korean pharmaceutical firm HLB Co., has received fast-track designation from the US Food and Drug Admi...

Bio & Pharma US affiliate of Korea's cell therapy company NK Max eyes NYSE listing in 3Q

NKGen Biotech, the US affiliate of South Korea's natural killer (NK) cell therapy developer NK Max, on Friday said it signed a letter of intent (LOI) ...